Corbus Pharmaceuticals Holdings Inc
NASDAQ:CRBP
Intrinsic Value
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serio... [ Read More ]
There is not enough data to reliably calculate the intrinsic value of CRBP.
Corbus Pharmaceuticals Holdings Inc's market capitalization is 395.5m USD.
CRBP stock price is 37.7 USD.
CRBP.
CRBP. Open DCF Valuation
CRBP. Open Relative Valuation
CRBP has upside potential of 49% compared to the average analyst price target.
Open Wall St Estimates
CRBP's long-term liabilties (35m USD) exceed its long-term assets (28m USD).
CRBP's ROE (Return on Equity) has significantly decreased in the last 3 years from -171% to -342%, and is approaching profitability.
CRBP's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -1 027% to -992%, and is approaching profitability.
CRBP's short-term liabilties (32m USD) exceed its short-term assets (24m USD).
CRBP has negative Operating Income for the last twelve months.
CRBP has negative Net Income for the last twelve months.
CRBP's ROE (Return on Equity) for the past 12 months is negative and is equal to -342%.
CRBP's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -992%.
CRBP has negative Free Cash Flow for the last twelve months.
CRBP has negative three-year average ROE (Return on Equity): -154%. The company is not efficient at transforming stockholders' equity into net income.
CRBP has negative three-year average ROIC (Return on Invested Capital): -776%. The company is not efficient at using invested capital to generate operating income.
CRBP's D/E (Debt to Equity) is very low and is equal to 0.
CRBP's Altman Z-Score is very low and is equal to -27.05.
CRBP doesn't generate enough operating income (-45m USD) to safely cover interest payments on its debt (3m USD).
Fundamental Analysis
Corbus Pharmaceuticals Holdings Inc
Balance Sheet Decomposition
Corbus Pharmaceuticals Holdings Inc
| Current Assets | 23.5m |
| Cash & Short-Term Investments | 20.9m |
| Other Current Assets | 2.6m |
| Non-Current Assets | 4.7m |
| PP&E | 4m |
| Other Non-Current Assets | 690.2k |
| Current Liabilities | 31.9m |
| Accounts Payable | 3.2m |
| Accrued Liabilities | 12.5m |
| Other Current Liabilities | 16.2m |
| Non-Current Liabilities | 3.3m |
| Other Non-Current Liabilities | 3.3m |
Earnings Waterfall
Corbus Pharmaceuticals Holdings Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-45.1m
USD
|
|
Operating Income
|
-45.1m
USD
|
|
Other Expenses
|
474k
USD
|
|
Net Income
|
-44.6m
USD
|
Free Cash Flow Analysis
Corbus Pharmaceuticals Holdings Inc
What is Free Cash Flow?
CRBP Profitability Score
Profitability Due Diligence
Corbus Pharmaceuticals Holdings Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Corbus Pharmaceuticals Holdings Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
CRBP Solvency Score
Solvency Due Diligence
Corbus Pharmaceuticals Holdings Inc's solvency score is 32/100. The higher the solvency score, the more solvent the company is.
Score
Corbus Pharmaceuticals Holdings Inc's solvency score is 32/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CRBP Price Targets Summary
Corbus Pharmaceuticals Holdings Inc
According to Wall Street analysts, the average 1-year price target for
CRBP
is 56.1 USD
with a low forecast of 52.52 USD and a high forecast of 60.9 USD.
Ownership
CRBP Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
CRBP Price
Corbus Pharmaceuticals Holdings Inc
| Average Annual Return | -58.17% |
| Standard Deviation of Annual Returns | 26.09% |
| Max Drawdown | -99% |
| Market Capitalization | 395.5m USD |
| Shares Outstanding | 10 490 000 |
| Percentage of Shares Shorted | 5.62% |
Company Profile
Corbus Pharmaceuticals Holdings Inc
Country
Industry
Market Cap
Dividend Yield
Description
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The company is headquartered in Norwood, Massachusetts and currently employs 41 full-time employees. The company went IPO on 2014-10-24. The Company’s pipeline includes anti-integrin monoclonal antibodies that block activation of TGFβ and small molecules that activate or inhibit the endocannabinoid system. The firm pipeline includes Anti-integrin monoclonal antibodies (mAbs), Cannabinoid receptor type 1 (CB1) and Lenabasum. The mAbs is for the treatment of cancer and fibrosis that inhibit the activation of Transforming growth factor β (TGFβ). Its CRB-601 is an anti-αvβ8 mAb being developed as a potential treatment for solid tumors in combination with existing therapies, including checkpoint inhibitors. Cannabinoid receptor type 1 (CB1) is an inverse agonist designed to treat obesity and related metabolic diseases. Lenabasum is a novel, synthetic, oral molecule that selectively activates cannabinoid receptor type 2 (CB2).
You don't have any saved screeners yet
